Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NAAA | Q02083 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849904 | 0.92 | POLB (0.49) | SMN1; SMN2NAAADRD2DRD4DRD3 | |
| SCHEMBL22767927 | 0.89 | CNR1 (0.50) | — | |
| SCHEMBL24849910 | 0.87 | DRD2 (0.47) | SMN1; SMN2NAAADRD2DRD4DRD3 | |
| SCHEMBL9978782 | 0.86 | NAAA (0.71) | SMN1; SMN2NAAAL3MBTL1THRATHRB | |
| SCHEMBL6437809 | 0.86 | NAAA (0.71) | SMN1; SMN2NAAAL3MBTL1THRATHRB | |
| SCHEMBL9979317 | 0.86 | NAAA (0.71) | SMN1; SMN2NAAAL3MBTL1THRATHRB | |
| SCHEMBL1978767 | 0.86 | NAAA (0.71) | SMN1; SMN2NAAAL3MBTL1THRATHRB | |
| SCHEMBL9979011 | 0.86 | NAAA (0.71) | SMN1; SMN2NAAAL3MBTL1THRATHRB | |
| SCHEMBL19326796 | 0.86 | NAAA (0.71) | SMN1; SMN2NAAAL3MBTL1THRATHRB | |
| SCHEMBL1977288 | 0.86 | NAAA (0.71) | SMN1; SMN2NAAAL3MBTL1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729621-A2 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | Massachusetts Institute of Technology (US) | 2026-04-22 | — | — | EP | claimed |
| US-12600990-B2 | MRNA induced expression of bone morphogenic protein and receptor and methods related thereto | MULLIN PATENTS, LLC | 2026-04-14 | — | — | US | claimed |
| US-20260061013-A1 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-05 | — | — | US | claimed |
| US-20260041754-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | HDT BIO CORP (US) | 2026-02-12 | — | — | US | claimed |
| EP-4687853-A1 | LIPID NANOPARTICLE COMPOSITIONS | Københavns Universitet (DK) | 2026-02-11 | — | — | EP | claimed |
| EP-3934673-B1 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | MASSACHUSETTS INST TECHNOLOGY (US) | 2026-01-07 | — | — | EP | claimed |
| US-12485163-B2 | Cancer therapy compositions and uses thereof | HDT BIO CORP. (US) | 2025-12-02 | — | — | US | claimed |
| US-20250295751-A1 | RNA VACCINES AGAINST INFECTIOUS DISEASES | HDT BIO CORP. | 2025-09-25 | — | — | US | claimed |
| US-12383589-B2 | Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228930-A1 | SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE | HDT BIO CORP. | 2025-07-17 | — | — | US | claimed |
| US-20230295257-A1 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | STRAND THERAPEUTICS INC. (US) | 2023-09-21 | — | — | US | claimed |
| US-11717548-B2 | Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-08-08 | — | — | US | claimed |
| EP-4185274-A1 | LIPIDNANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | Strand Therapeutics Inc. (US) | 2023-05-31 | — | — | EP | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2023049777-A2 | NUCLEIC ACID SENSOR AGONIST COMPOSITIONS AND USES THEREOF | HDT BIO CORP. (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2023049753-A2 | COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN BINDING PROTEINS | HDT BIO CORP. (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2023049636-A2 | CANCER THERAPY COMPOSITIONS AND USES THEREOF | HDT BIO CORP. (US) | 2023-03-30 | — | — | WO | claimed |
| EP-3934673-A1 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | Massachusetts Institute of Technology (US) | 2022-01-12 | — | — | EP | claimed |
| WO-2020185293-A1 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-17 | — | — | WO | claimed |
| US-20200281994-A1 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-09-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061013-A1 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | LSM12, IL2, CASP12 | SMN1; SMN2 2204/4885NAAA 482/4885DRD2 4636/4885 |
| US-12600990-B2 | MRNA induced expression of bone morphogenic protein and receptor and methods related thereto | BMP2, BMP1, BMPR2 | SMN1; SMN2 3285/4885NAAA 3710/4885DRD2 4390/4885 |
| US-20260041754-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | ITGAL, ITGA2B, ITGA2 | SMN1; SMN2 761/4885NAAA 3991/4885DRD2 1743/4885 |
| US-20230295257-A1 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | CASP12, RNMT, RBM12 | SMN1; SMN2 2629/4885NAAA 1264/4885DRD2 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.